NSE
BSEThe Quarter story
The two most recent quarterly results, compared side-by-side.
Quick Heal faces revenue and profitability pressure, but strong cost control, rising deferred revenue, and steady promoter backing point to underlying resilience.
Deferred revenue grew from ₹16.6 Cr to ₹52.3 Cr from Q1 FY26 to Q1 FY27, confirming strong future billing visibility.
Consolidated revenue dropped from ₹57.2 Cr to ₹45.0 Cr from Q1 FY26 to Q1 FY27, highlighting weakening top-line momentum.
Gross margin recovered from 95.9% to 98.2% from Q3 FY26 to Q1 FY27, showing resilient pricing power.
EBITDA margin collapsed from -17.0% to -39.1% from Q1 FY26 to Q1 FY27, revealing severe profitability erosion.
General administration costs fell from ₹17.5 Cr to ₹12.6 Cr from Q3 FY26 to Q1 FY27, reflecting improved operational efficiency.
Consumer segment revenue fell from ₹32 Cr to ₹19 Cr from Q1 FY26 to Q1 FY27, signaling weak segment demand.
Promoter shareholding held steady at 72% from Q1 FY26 to Q1 FY27, reflecting unwavering management confidence.
Market cap halved from ₹20,032.63 Cr to ₹9,354.17 Cr from Q1 FY26 to Q1 FY27, reflecting sharp valuation contraction.
